AI in Genomics Market Report 2026

The AI in genomics market size has grown exponentially in recent years. It will grow from $1.51 billion in 2025 to $2.18 billion in 2026 at a compound annual growth rate (CAGR) of 44.6%. The growth in the historic period can be attributed to increasing availability of large-scale genomic datasets, declining cost of dna sequencing technologies, expansion of genomics research initiatives, growing collaboration between AI developers and biotech firms, improved computational biology capabilities.

The AI in genomics market size is expected to see exponential growth in the next few years. It will grow to $9.32 billion in 2030 at a compound annual growth rate (CAGR) of 43.7%. The growth in the forecast period can be attributed to increasing adoption of precision medicine approaches, rising investments in ai-powered drug discovery, expansion of population genomics projects, growing demand for personalized healthcare solutions, advancements in deep learning genomic models. Major trends in the forecast period include increasing adoption of ai-driven genome analysis platforms, rising use of machine learning for variant detection, growing integration of AI in gene editing workflows, expansion of cloud-based genomic data processing, enhanced focus on high-accuracy pattern recognition.

The growing adoption of personalized medicine approaches is expected to drive the growth of the AI in genomics market in the coming years. Personalized medicine, also known as precision medicine, is a healthcare approach that considers individual variations in patients’ genes, environments, and lifestyles. The rising adoption of personalized medicine is driven by the increasing prevalence of chronic and complex diseases, as these approaches enable treatments to be tailored to individual patient profiles, improving efficacy and reducing adverse effects. AI in genomics accelerates the analysis of complex genetic data, supporting personalized medicine by customizing treatments and interventions based on an individual’s unique genetic profile. For example, in February 2024, the Personalized Medicine Coalition, a US-based hospital and healthcare organization, reported that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. Thus, the increasing use of personalized medicine approaches is fueling the growth of the AI in genomics market.

Major companies in the AI in genomics market are focusing on developing innovative solutions, such as drug discovery platforms, to enhance precision healthcare and research efficiency. Drug discovery platforms are technologies or software systems that use computational tools, AI, or lab automation to identify, design, and optimize new drug candidates efficiently. For instance, in March 2023, Genomic Vision, a France-based biotechnology company specializing in diagnostic solutions for genetic diseases and cancers, launched FiberSmart, an AI-powered software that enables high-resolution visualization and analysis of long DNA fibers. This technology aims to improve the precision and effectiveness of diagnosing and treating genetic diseases by analyzing large datasets to identify patterns and insights beyond human capability.

In September 2025, SeqOne S.A.S., a France-based healthcare technology company, acquired Congenica for an undisclosed amount. Through this acquisition, SeqOne aims to strengthen its global leadership in AI-powered genomic medicine by combining advanced AI analytics with trusted clinical interpretation services. Congenica Ltd is a UK-based healthcare technology company specializing in AI in genomics.

Major companies operating in the AI in genomics market are International Business Machines Corporation; Microsoft Corp.; NVIDIA Corporation; Deep Genomics Inc.; BenevolentAI Ltd.; Fabric Genomics Inc.; Verge Genomic Inc.; Freenome Holdings Inc.; MolecularMatch Inc.; SOPHiA GENETICS SA; Data4Cure Inc.; PrecisionLife Ltd.; Genoox Ltd.; Lifebit Ltd.; Empiric Logic Ltd.; FDNA Inc.; DNAnexus Inc.; Engine Biosciences Pte Ltd.; 4baseCare; Congenica Ltd.; CytoReason Ltd.; Emedgene Technologies LTD; Illumina Inc.; Lifebit Biotech Ltd.; Mendel.ai; Predictive Oncology Inc.; Tempus Labs Inc.; 10x Genomics Inc.; Repositive Limited; Genedata AG; Global Gene Corp; Nference Inc.; Bluebee Holding B.V.; Genomenon Inc.

North America was the largest region in the AI in genomics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the AI in the genomics market report during the forecast period. The regions covered in the AI in genomics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the AI in genomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the AI in genomics market by increasing costs of imported high-performance servers, data storage systems, networking equipment, and specialized semiconductor components required for large-scale genomic data processing. Research institutions and biotech companies in North America and Europe are most affected due to reliance on advanced imported computing infrastructure, while Asia-Pacific faces cost pressures on hardware-intensive deployments. These tariffs are raising capital expenditure and slowing infrastructure upgrades for genomics research. However, they are also encouraging local manufacturing of compute hardware, regional cloud infrastructure investments, and optimization of software-centric AI genomics solutions.

The AI in genomics market research report is one of a series of new reports that provides AI in genomics market statistics, including AI in genomics industry global market size, regional shares, competitors with a AI in genomics market share, detailed AI in genomics market segments, market trends and opportunities, and any further data you may need to thrive in the AI in genomics industry. This AI in genomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

AI in genomics refers to a collection of computer tools utilized by genomics researchers to handle and decipher critical information embedded in large datasets generated from DNA sequencing and other biological processes. These algorithms are designed to identify patterns and abnormalities within genomic data, aiding researchers in understanding the complexities of the human genome.

The main components involved in AI in genomics include hardware, software, and services, with machine learning and computer vision as the key technologies. Hardware encompasses both external and internal components and equipment that enable users to perform various operations such as input, output, storage, communication, and processing. The main functionalities of AI in genomics include genome sequencing, gene editing, and others, and these technologies find applications in diverse areas, including drug discovery and development, precision medicine, diagnostics, and more. The major end-users of AI in genomics include pharmaceutical and biotech companies, healthcare providers, research centers, and other entities involved in genomics research.

The AI in genomics market includes revenues earned by entities by providing services such as computer vision, time series analysis, automatic speech recognition, and natural language processing. The market value includes the value of related goods sold by the service provider or included within the service offering. The AI in genomics market also includes sales of neural network hardware, powered diagnostics and imaging machine which are used in providing AI in genomics services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.